SAN FRANCISCO--(EON: Enhanced Online News)--MPM Capital expands its San Francisco investment team with the appointment of Ed Hurwitz, JD, MBA, as Managing Director. With more than 25 years of biotech and life science investment, finance and operations experience, Hurwitz brings to this role a demonstrated track record of overseeing innovative investment funds, sourcing profitable investment opportunities and working with portfolio companies to develop breakthrough products and exceed financial goals.
“We’re thrilled to welcome Ed to MPM. MPM and its portfolio companies will benefit from his venture capital and industry knowledge, reflected in his ability to build, manage and exit industry-leading companies”
“We’re thrilled to welcome Ed to MPM. MPM and its portfolio companies will benefit from his venture capital and industry knowledge, reflected in his ability to build, manage and exit industry-leading companies,” said Ansbert Gadicke, MPM Managing Director and Co-Founder. Added Gadicke’s Co-Founder and MPM Managing Director Luke Evnin, “Ed has the right combination of skills to make significant contributions to our investment team and to help us continue to drive medical discoveries that improve patients’ lives.”
Hurwitz was most recently Founder and Managing Director of Precision BioVentures LLC where he focused on developing novel investment strategies and building a successful portfolio of businesses. While there, he co-founded Viewpoint Therapeutics, an innovative ophthalmology company. Prior to this, he was a Director of two funds at Alta Partners — Alta BioPharma Management III and Alta Partners Management VIII. Hurwitz currently serves on the Boards of Directors for Applied Genetic Technologies Corporation, Macrogenics, Inc. and Viewpoint Therapeutics. While at Alta, Hurwitz also led investments and served on the Boards of Directors of Avid Radiopharmaceuticals (acquired by Lilly), Calistoga Pharmaceuticals (acquired by Gilead), Cara Therapeutics, FoldRx Pharmaceuticals (acquired by Pfizer), and Taligen Therapeutics (acquired by Alexion).
Over the course of his career, Hurwitz has been a Senior Vice President and CFO of Affymetrix, a pioneer microarray supplier, and a biotechnology research analyst for both Robertson Stephens & Company and Smith Barney Shearson. Prior to that he practiced law at Cooley Godward LLP. Hurwitz earned his JD and MBA degrees from the University of California, Berkeley’s Boalt School of Law and Haas School of Business, and his BA in Molecular Biology from Cornell University.
About MPM Capital — MPM Capital (http://www.mpmcapital.com) is an early-stage life sciences venture firm founding and investing in companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. MPM’s portfolio of companies aims to revolutionize the face of medicine across multiple areas including cancer, diabetes, obesity, pain, eHealth and more. With its experienced and dedicated team of operating executives and medical and scientific advisory board, MPM is powering novel medical breakthroughs that transform patient lives.